Targeted treatments for cervical cancer: A review

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 315-328

  Peralta Zaragoza, Oscar ^a   Bermúdez Morales, Víctor Hugo ^a   Pérez Plasencia, Carlos ^b,c   Salazar León, Jonathan ^a   Gómez Cerón, Claudia ^a   Madrid Marina, Vicente ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Cervical cancer; Clinical trials; Gene therapy; HPV E6 and E7 oncogenes; SiRNAs

Indexed keywords

ADXS 11 001; AMOLIMOGENE BEPIPLASMID; BACTERIAL VECTOR BASED VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; E6 E7 FUSION PROTEIN; GEMCITABINE; GENDICINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN PAPILLOMAVIRUS PEPTIDE BASED VACCINE; HYBRID PROTEIN; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 12; LINE VECTOR BASED VACCINE; MODIFIED VACCINIA ANKARA E2 VIRUS PROTEIN; PLACEBO; PROTEIN E7; RNA VACCINE; RO 5217790; SMALL INTERFERING RNA; TG 4001; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VGX 3100; VIRAL VECTOR BASED VACCINE; VIRUS PROTEIN; WART VIRUS VACCINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CONDYLOMA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GENE SILENCING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRAL GENE THERAPY;

EID: 84873931378     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S25123     Document Type: Review

References (80)

1. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010. WHO/ICO. 2010; November 15:1-68. http://www.who.int/hpvcentre. Accessed on July 31, 2012.
2. Zur Hausen H. Papillomaviruses to vaccination and beyond. Biochemistry (Mosc). 2008;73(5):498-503.
3. de Sanjose S, Quint WG, Alemany L, et al; Retrospective International Survey and HPC Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross- sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056.
4. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006;110(5):525-541.
5. Wise-Draper TM, Wells SI. Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci. 2008;13:1003-1017.
6. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550-560.
7. Huang CF, Monie A, Weng WH, Wu TC. DNA vaccines for cervical cancer. Am J Transl Res. 2010;2(1):75-87.
8. Saito Ramalho A, Dantas Lopes A, Talans A, et al. Molecular targets for therapeutic interventions in human papillomavirus-related cancers. Oncol Rep. 2010;24(6):1419-1426.
9. Rossbach M. Therapeutic implications of microRNAs in human cancer. J Nucleic Acids Investig. 2010;2(e3):17-22.
10. Mariani L, Venuti A. HPV vaccine: an overview of immune respose, clinical protections, and new approaches for the future. J Trans Med. 2010;8:105.
11. Gissmann L, Nieto K. The therapeutics vaccines: is it feasible? Arch Med Res. 2009;40(6):493-498.
12. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res. 2008;14(1):178-187.
13. Bolhassani A, Mohit E, Rafati S. Different spectra of therapeutic vaccine development against HPV infections. Hum Vaccin. 2009;5(10): 671-689.
14. Ma B, Xu Y, Hung CF, et al. HPV and therapeutic vaccines: Where we are in 2010? Curr Cancer Ther Rev. 2010;6:81-103.
15. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms intermediacy of H(2) O(2)- and p53-dependent pathways. J Biol Chem. 2004;279(24): 25535-25543.
16. Mielgo A, Torres VA, Clair K, Barbero S, Stupack DG. Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene. 2009;28(40): 3551-3562.
17. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691-1701.
18. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28:578-590.
19. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents. Science. 2012;334:1573-1577.
20. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47-59.
21. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2002;2:185-194.
22. Miller RL, Meng TC, Tomai MA. The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect. 2008;21:69-87.
23. Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol. 2003: 149:5-8.
24. Van Seters M, van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008; 358:1465-1475.
25. Daayana S, Ekord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulva intraepithelial neoplasia. Br J Cancer. 2010;102:1129-1136.
26. Chuang CM, Monei A, Hung CH, Wu TC. Treatment with imiqimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Bio Sci. 2010;17:32-40.
27. Suzuki E, Sun J, Kapoor V, Jassar As, Albelda SM. Gemcitabine has significant immunomodulatory activity in murine models independent of its cytotoxic effects. Cancer Biol Ther. 2007;6:880-885.
28. Lui WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010; 102:115-123.
29. Machado FA, Janssens J P, Michelin MA, Murta EF. Immune response and immunotherapy in intraepithelial and invasive lesions of the uterine cervix. Clin Exp Obstet Gynecol. 2012;39(1):27-31.
30. Bermúdez-Morales VH, Peralta-Zaragoza O, Madrid-Marina V. Gene therapy with cytokines against cervical cancer. Salud Publica Mex. 2005;47(6):458-468.
31. Leachman SA, Tigelarr M, Shlyankevich M, et al. Granulocyte- macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus-rabbit model. J Virol. 2000;74: 8700-8708.
32. Colombo M P, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155-168.
33. Indrová M, Bieblová J, Rossowska J, et al. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int J Oncol. 2009;34(1): 173-179.
34. Lui V W, He Y, Falo L, Huang L. Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor. Hum Gene Ther. 2002;13:177-185.
35. Ahn WS, Bae SM, Kim TY, et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/ E7-associated cervical cancer animal model. Hum Gene Ther. 2003; 14(15):1389-1399.
36. Indrová M, Bubenik J, Mikyskova R, et al. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I tumours: Effects of CBM-4 A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int J Oncol. 2003;22: 691-695.
37. Bergot AS, Kassianos A, Frazer IH, et al. New approaches to Immunotherapy for HPV associated Cancers. Cancer. 2011;3: 3461-3495.
38. Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, et al. Cell surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target. 2005;13(2): 89-98.
39. Sewell DA, Shahabi V, Gunn GR, et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor- associated antigen human papillomavirus-16 E7. Cancer Res. 2004; 64(24):8821-8825.
40. Echchannaoui H, Bianchi M, Baud D, et al. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun. 2008;76(5): 1940-1951.
41. Hsieh CJ, Kim T W, Hung C F, et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding human papillomavirus type 16 E7 protein. Clin Vaccine Immunol. 2008;15(5): 817-824.
42. Lee DW, Anderson ME, Wu S, et al. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. Arch Otolaryngol Head Neck Surg. 2008;134(12):1316-1323.
43. Liao JB, Publicover J, Rose JK, et al. Single-Dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papilloma- virus type 16 E7 protein. Clin Vaccine Immunol. 2008;15(5):817-824.
44. Zhou L, Zhu T, Ye X, et al. Long-term protection against human papillomavirus E7-positive tumor by a single vaccination of adeno associated virus vectors encoding a fusion protein of inactivated E7 of human papillomavirus 16/18 and heat shock protein 70. Hum Gene Ther. 2010;21(1):109-119.
45. Daemen T, Riezebos-Brilman A, Regts J, et al. Superior therapeutic efficacy of alphavirus-mediated immunization against human papillomavirus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther. 2004;9(5):733-742.
46. Davidson EJ, Faulkner RL, Sehr P, et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunization in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine. 2004;22(21-22):2722-2729.
47. Baldwin PJ, van der Burg SH, Boswel CM, et al. Vaccinia expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res. 2003;9(14):5205-5213.
48. Corona-Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther. 2004;15(5):421-431.
49. García-Hernández E, González-Sánchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with M VA E2 recombinant vaccine. Cancer Gene Ther. 2006;13(6):592-597.
50. Kenter GG, Welters MJ, Valentijin AR, et al. Vaccination against HPV-16 oncoproteins for vulva intraepithelial neoplasia. N Engl J Med. 2009;361:1838-1847.
51. Vambutas A, DeVoti J, Nouri M, et al. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre- clinical cottontail rabbit papillomavirus model. Vaccine. 2005;23(45): 5271-5280.
52. Chen W, Huang L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol Pharm. 2008;5(3): 464-471.
53. Sharma RK, Elpek KG, Yolcu ES, et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res. 2009;69(10):4319-4926.
54. Kim TG, Kim CH, Won EH, et al. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology. 2004;112(1):117-125.
55. Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother. 2005;54(12):1180-1190.
56. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1study of HPV16-specific immunotherapy with E6E7 fusion protein and Iscomatrix adjuvant in women with cervical intraepithelial neoplasia. Vaccine. 2004;23(2): 172-181.
57. Liao C W, Chen CA, Lee CN, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res. 2005; 65(19):9089-9098.
58. Hung CF, Calizo R, Tsai YC, He L, Wu TC. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine. 2007;25(1):127-135.
59. Lu D, Hoory T, Monie A, Wu A, Wang MC, Hung CF. Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009;27(32):4363-4369.
60. Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol. 2008;180(10): 7019-7027.
61. Huang CH, Peng S, He L, et al. Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther. 2005;12(15): 1180-1186.
62. Martinon F, Brochard P, Ripaux M, et al. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus. Vaccine. 2008;26(4):532-545.
63. Cheng W F, Hung CF, Hsu KF, et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther. 2002;13(4):553-568.
64. Mikysková R, Indrová M, Símová J, et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16- associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol. 2004;24(1):161-167.
65. Kim JH, Kang TH, Noh KH, et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death. Immunol Lett. 2009;122(1):58-67.
66. Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: A phase I escalating-dose trial. J Virol. 2008;82(4): 1968-1979.
67. ABEDIA [webpage on the Internet]. Database of clinical trials [updated Jun 2012]. Available from: http://www.abedia.com/wiley/index.html. Accessed August 1, 2012.
68. US National Institutes of Health [website] Database of clinical trials. [Updated July 30, 2012]. Available from: http://clinicaltrials.gov/ct2/home. Accessed on August 8, 2012.
69. Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine. 2001;19(17-19):2549-2556.
70. Sima N, Wang S, Wang W, et al. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol Oncol. 2007; 106(2):299-304.
71. Liu Z, Sall A, Yang D. MicroRNA: an emerging therapeutic target and intervention tool. Int J Mol Sci. 2008;9:978-999.
72. Sioud M, Sorensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun. 2003;312: 1220-1225.
73. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-553.
74. Jiang M, Milner J. Selective silencing of viral gene expression in HPV- positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene. 2002;21:6041-6048.
75. Niu XY, Peng ZL, Duan WQ, Wang H, Wang P. Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer. 2006;16:743-751.
76. Salazar-León J, Reyes-Román F, Meneses-Acosta A, et al. Silencing of HPV16 E6 and E7 oncogenic activities by small interference RNA induces autophagy and apoptosis in human cervical cancer cells. J Nucleic Acids Investig. 2011;2:e10:59-69.
77. Chang JT, Kuo T F, Chen YJ, et al. Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. Cancer Gene Ther. 2010;17(12):827-836.
78. Takuma F, Miyuki S, Eri I, et al. Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncology. 2006;29: 541-548.
79. Wu S Y, Singhania A, Burgess M, et al. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Ther. 2011;18(1):14-22.
80. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: Promises and challenges. Oncologist. 2005;10: 528-538.